Shares of Bicara Therapeutics—a biopharmaceutical company backed by Indian billionaire Kiran Mazumdar-Shaw—surged about 42% ...
Aethlon Medical receives Ethics Committee approval for Hemopurifier cancer trial in India: San Diego Saturday, September 21, 2024, 09:00 Hrs [IST] Aethlon Inc., a medical therapeu ...
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...
Zacks.com on MSN17h
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ DrugsThis week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...
ThePrint on MSN20h
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catchIn head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback